PEP/NEWS — Peptide intel. Daily.

What if your sex life didn't have to decline with age — but could actually get better? Susan Bratton, intimacy expert and educator to over 1.5 million people worldwide, joins Dr. Debra Durst for one of the most wide-ranging, honest, and g

Use Code THOMAS20 for 20% off Timeline's Mitopure: http://timeline.com/thomas This video does contain a paid partnership with a brand that helps to support this channel. It is because of brands like this that we are able to provide the con

A pilot study in Aging Cell found that spermidine reduced markers of immune aging and improved vaccine responses in healthy older adults. The sample is small, but the dual endpoint — less senescence plus better immune function — is a compelling early signal.

The Alliance for Longevity Initiatives is bringing policymakers, regulators, and researchers to Georgetown University this summer. The H-SPAN Summit is the clearest sign yet that longevity science is pushing into the American policy mainstream.

Oligomerix finished its Phase 1a trial of an oral drug targeting tau — one of the brain's most destructive proteins in Alzheimer's. A pill that targets tau would be a major practical advance over infusion-based therapies currently in the pipeline.

Commercial multi-modal Alzheimer's screening just launched in the UK. The push is driven by the arrival of disease-modifying drugs — suddenly, early detection has a point. At-home testing may follow.

Scientists built a CRISPR tool that kills cells carrying a specific RNA strand. It worked on cancerous and virus-infected cells in early tests. The precision is what makes it notable — no bystander damage, just targeted cell elimination.

Scribe Therapeutics got Australian regulatory clearance to test STX-1150 in humans. The drug uses epigenetic editing — not permanent DNA changes — to lower LDL cholesterol. One treatment could potentially hold for years.

Nourish raised $100 million to expand its AI-driven nutrition platform. The bet is that lasting metabolic improvement requires behavior change, not just prescriptions. GLP-1 drugs are reshaping who shows up to these clinics.

Cutting methionine (an amino acid found in meat and eggs) extended lifespan in yeast by switching on autophagy — the cell's internal cleanup process. The mechanism runs through protein methylation, not the better-known nitrogen-starvation pathway. Implications for dietary restriction research in mammals are worth watching.

Cyclarity Therapeutics released Phase 1 safety data for UDP-003, a cyclodextrin molecule that targets 7-ketocholesterol — a toxic oxidized form of cholesterol that clogs arteries. Most cardiovascular drugs slow plaque buildup. This one aims to clear it.

A new review in PLOS Biology argues that the late-life collapse of the gut microbiome is not random. The immune system actively shapes microbial composition for most of life — and when that surveillance falters with age, the microbiome deteriorates with it.

Rather than relitigating whether adult neurogenesis exists, researchers propose moving directly to strategies that activate dormant hippocampal stem cells. The goal: build resilience against cognitive aging using the brain's own repair capacity.

Animal data shows that pulsed ultrasound can shift gut microbial composition toward a more youthful profile — and that this change improved muscle function. The mechanism runs through the microbiome, not direct muscle stimulation.